Figure 3
From: Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-α treatment
COMP-C3b decreases in rheumatoid arthritis (RA) patients on tumor necrosis factor (TNF)-α inhibition. RA patients (n = 90) receiving infliximab were measured for COMP-C3b (a), C-reactive protein (CRP) (b), and COMP (c) at baseline, after 6 weeks, and after 3 months of treatment. Statistical significance of changes in these parameters was measured with a Friedman test. ***P < 0.001; **P < 0.01; *P < 0.05; ns, not significant.